Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ORGANIZATION
ORGANIZATION
- Hiroyuki Kawabata Joins PhRMA as Sr. Assistant Japan Representative
July 16, 2021
- Downloads of FPMAJ’s E-Labeling App on Track to Target 50,000 as Legal Enforcement Approaches
July 14, 2021
- Japan Patient Advocates Want Drugs for Later-Stage Alzheimer’s
July 13, 2021
- New Trade Group for Established Drugs to Launch in Japan
July 13, 2021
- FIRM Calls for Separate Pricing System for Regenerative Medicine Products: Chair
July 13, 2021
- JMA Frets Pricey Dementia Meds, to Explore Ways to Keep Universal Coverage
July 9, 2021
- High-Priced Drugs Should Be Discussed Carefully Based on Characteristics of Diseases and Treatments: JMA Exec
July 1, 2021
- More than 80% of Pharmacists Feel Impact of Generic Supply Delays on Business: Survey
June 23, 2021
- Patient Group Wants More R&D Spending on Pancreatic Cancer
June 15, 2021
- Saitama-Based Hospital Group Introduces Formulary in 18 Therapeutic Areas, Aims to Spread Know-How in Region
June 15, 2021
- FPMAJ Urges Caution with Market Expansion Re-Pricing, Says Add’l Indications Now Seen as Price Cut Risk
June 14, 2021
- FPMAJ Drug Price Report Rebuts Issues Raised over Cost-Plus Method, PMP and More
June 14, 2021
- PhRMA Posts Its Position on Japan CEA Scheme on Website
June 11, 2021
- Eisai’s Akana Re-Elected as FPMAJ’s Drug Pricing Chief
June 11, 2021
- Terumo’s Mimura Elected New Medical Devices Chief; Reimbursement Debate Ahead for SaMD
June 9, 2021
- Experts Eye Macroeconomic Indexing of Drug Costs to Keep Innovation Afloat: INES Proposal
May 31, 2021
- Ken Suzuki Returns to JPWA Reins after 2 Years
May 28, 2021
- JPMA Positive on Use of Clinical Research Data in Submissions, but Wary of Funding Database
May 26, 2021
- Ken Suzuki Likely to Come Back as JPWA Chief after 2 Years
May 25, 2021
- JPMA Will Work towards Price Maintenance for On-Patent Medicines: New President
May 24, 2021
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…